Eleven Million Euros for Researching New Types of Cancer Treatment

The German Research Foundation (DFG) will begin providing support for the collaborative research center collaborative research centers (Sonderforschungsbereich, SFB), CRC 1479 “OncoEscape – Oncogenically Driven Immune Escape” on 1 July 2021. The CRC is receiving almost eleven million euros for an initial four years. The researchers aim to investigate how certain genetic characteristics first contribute to the formation of tumor cells and later to their escape from the immune system. Improved understanding of what is known as immune escape is particularly important and essential for developing treatments for advanced cancers. The coordinator of the CRC is Robert Zeiser, Head of the Tumor Immunology and Immune Modulation Section of the Department of Medicine I at the University Medical Center Freiburg. The research groups taking part in the project belong to the University Medical Center Freiburg, the University of Freiburg, the Max Planck Institute of Immunobiology and Epigenetics in Freiburg, the German. Cancer Research Center in Heidelberg, and the Georg-Speyer-Haus in Frankfurt.